--- title: "Calix shares fall 7% after Q2 beat as AI-driven memory costs squeeze margins" type: "News" locale: "en" url: "https://longbridge.com/en/news/293360079.md" description: "Calix shares fell ~7% despite beating Q2 earnings estimates, as AI-driven memory cost surges squeezed gross margins. Revenue hit a record $293.3M, up 21.3% YoY, driven by strong demand for its AI-native platform. However, non-GAAP gross margin dropped to 54.8% due to higher component costs, which management is passing on via surcharges. The company forecasts Q3 revenue of $301M-$307M and gross margins of 50.5%-53.5%, reflecting continued cost pressures." datetime: "2026-07-21T15:01:47.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/293360079.md) - [en](https://longbridge.com/en/news/293360079.md) - [zh-HK](https://longbridge.com/zh-HK/news/293360079.md) generator: "portal-rs" --- # Calix shares fall 7% after Q2 beat as AI-driven memory costs squeeze margins Calix (CALX) shares fell over ~7% to ~$35.78 on Tuesday, even after the company reported better-than-expected second-quarter results, as investors focused on pressure on gross margins from higher memory component costs. On a year-to-date basis, the stock has significantly underperformed the broader S&P 500 (SP500), falling 32.63% compared with the ... ### Related Stocks - [CALX.US](https://longbridge.com/en/quote/CALX.US.md) - [.SPX.US](https://longbridge.com/en/quote/.SPX.US.md) ## Related News & Research - [AI Was Supposed to Kill Wix. Google Just Gave It a Way to Fight Back.](https://longbridge.com/en/news/297433684.md) - [AI Winners, Victims, and the One Stock to Sell Now](https://longbridge.com/en/news/297431483.md) - [The Bot Now Clicks Buy: Your AI Is About To Start Spending Your Money](https://longbridge.com/en/news/297424265.md) - [As AI evolves, Tableau talks direction ahead of Dreamforce](https://longbridge.com/en/news/297559547.md) - [The Bull Case For Oracle (ORCL) Could Change Following Its Expanded Clinical AI Agent Rollout](https://longbridge.com/en/news/297431787.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**